logo
Plus   Neg
Share
Email

McCormick Reinstates FY20 Outlook; Announces 2-for-1 Stock Split - Quick Facts

While reporting financial results for the third quarter on Tuesday, McCormick & Co., Inc. (MKC) reinstated its adjusted earnings and sales guidance for the full year 2020, reflecting strong business performance driven by expected sales growth.

For fiscal 2020, the company now projects earnings in a range of $5.60 to $5.68 per share and adjusted earnings in a range of $5.64 to $5.72 per share on sales growth at the upper end of a 4 to 5 percent range, which in constant currency is a 5 to 6 percent growth rate.

McCormick previously withdrew its fiscal 2020 guidance on March 31, 2020, due to the uncertainty of the duration and extent of the coronavirus (COVID-19) pandemic impact.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $5.76 per share on sales growth of 3.4 percent to $5.53 billion for the year. Analysts' estimates typically exclude special items.

McCormick's Board of Directors also approved a 2-for-1 stock split of the company's common and common non-voting shares to be distributed on November 30, 2020 to stockholders of record as of November 20, 2020. The company last completed a stock split in April 2002.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walmart and Sam's Club announced options for customers to safely dispose unused, unwanted and expired medication throughout the year. With this, the retail giant aims to help the public from potential danger for misuse and abuse of prescription medications. On Saturday, October 24, the company will host in-person medication disposal events at select store and club locations across U.S. Telecom giant AT&T, Inc. reported Thursday a 24 percent decline in profit for the third quarter, primarily hurt by lower revenues across all its operating segments amid the impact from COVID-19 pandemic. Adjusted earnings for the quarter met analysts' expectations, while quarterly revenues topped their estimates. A Brazilian volunteer, who participated in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University, has died, Brazilian health authority Anvisa said. Oxford university reportedly confirmed the plan to continue the trial after careful assessment that there have been no concerns about safety of the clinical trial.
Follow RTT